Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152941 | 0.85 | LMNA (0.57) | MEN1KMT2AMAPTALDH1A1MCL1 | |
| SCHEMBL5895761 | 0.84 | KAT6A (0.43) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL5895771 | 0.84 | KAT6A (0.43) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL5895781 | 0.84 | KAT6A (0.43) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL5923490 | 0.83 | MEN1 (0.42) | MEN1KMT2AMAPTALDH1A1MCL1 | |
| SCHEMBL5923497 | 0.83 | MEN1 (0.42) | MEN1KMT2AMAPTALDH1A1MCL1 | |
| SCHEMBL2153035 | 0.83 | MAPT (0.45) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2153032 | 0.83 | MAPT (0.45) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2152907 | 0.81 | MAPT (0.45) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5895612 | 0.80 | ALDH1A1 (0.48) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833789-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS BV (NL) | 2011-07-06 | — | — | EP | disclosed |
| US-7732621-B2 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP ASSETS B.V. (NL) | 2010-06-08 | — | — | US | disclosed |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| EP-1833789-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSMIP Assets B.V. (NL) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069799-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS B.V. (NL) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676838-A1 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP Assets B.V. (NL) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | IDO2, IDO1, KYNU | MEN1 3646/4885KMT2A 779/4885MAPT 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.